206 related articles for article (PubMed ID: 32877803)
21.
Loganathan L; Muthusamy K; Jayaraj JM; Kajamaideen A; Balthasar JJ
J Biomol Struct Dyn; 2019 Sep; 37(14):3637-3648. PubMed ID: 30204055
[TBL] [Abstract][Full Text] [Related]
22. Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020).
Mehta CC; Bhatt HG
Expert Opin Ther Pat; 2021 Jul; 31(7):645-661. PubMed ID: 33567917
[TBL] [Abstract][Full Text] [Related]
23. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
24. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
[TBL] [Abstract][Full Text] [Related]
25. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a Novel Triazolopyridine Derivative as a Tankyrase Inhibitor.
Ryu H; Nam KY; Kim HJ; Song JY; Hwang SG; Kim JS; Kim J; Ahn J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298950
[TBL] [Abstract][Full Text] [Related]
27. Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities.
Zamudio-Martinez E; Herrera-Campos AB; Muñoz A; Rodríguez-Vargas JM; Oliver FJ
J Exp Clin Cancer Res; 2021 Apr; 40(1):144. PubMed ID: 33910596
[TBL] [Abstract][Full Text] [Related]
28. Tankyrase is necessary for canonical Wnt signaling during kidney development.
Karner CM; Merkel CE; Dodge M; Ma Z; Lu J; Chen C; Lum L; Carroll TJ
Dev Dyn; 2010 Jul; 239(7):2014-23. PubMed ID: 20549720
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
[TBL] [Abstract][Full Text] [Related]
30. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.
Bregman H; Gunaydin H; Gu Y; Schneider S; Wilson C; DiMauro EF; Huang X
J Med Chem; 2013 Feb; 56(3):1341-5. PubMed ID: 23316926
[TBL] [Abstract][Full Text] [Related]
32. Structural basis of tankyrase activation by polymerization.
Pillay N; Mariotti L; Zaleska M; Inian O; Jessop M; Hibbs S; Desfosses A; Hopkins PCR; Templeton CM; Beuron F; Morris EP; Guettler S
Nature; 2022 Dec; 612(7938):162-169. PubMed ID: 36418402
[TBL] [Abstract][Full Text] [Related]
33. Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
Shirai F; Mizutani A; Yashiroda Y; Tsumura T; Kano Y; Muramatsu Y; Chikada T; Yuki H; Niwa H; Sato S; Washizuka K; Koda Y; Mazaki Y; Jang MK; Yoshida H; Nagamori A; Okue M; Watanabe T; Kitamura K; Shitara E; Honma T; Umehara T; Shirouzu M; Fukami T; Seimiya H; Yoshida M; Koyama H
J Med Chem; 2020 Apr; 63(8):4183-4204. PubMed ID: 32202790
[TBL] [Abstract][Full Text] [Related]
34. Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition Domain of Tankyrase.
Xu W; Lau YH; Fischer G; Tan YS; Chattopadhyay A; de la Roche M; Hyvönen M; Verma C; Spring DR; Itzhaki LS
J Am Chem Soc; 2017 Feb; 139(6):2245-2256. PubMed ID: 28084734
[TBL] [Abstract][Full Text] [Related]
35. Tankyrase Requires SAM Domain-Dependent Polymerization to Support Wnt-β-Catenin Signaling.
Mariotti L; Templeton CM; Ranes M; Paracuellos P; Cronin N; Beuron F; Morris E; Guettler S
Mol Cell; 2016 Aug; 63(3):498-513. PubMed ID: 27494558
[TBL] [Abstract][Full Text] [Related]
36. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
[TBL] [Abstract][Full Text] [Related]
37. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
38. Tissue-Specific Regulation of the Wnt/β-Catenin Pathway by PAGE4 Inhibition of Tankyrase.
Koirala S; Klein J; Zheng Y; Glenn NO; Eisemann T; Fon Tacer K; Miller DJ; Kulak O; Lu M; Finkelstein DB; Neale G; Tillman H; Vogel P; Strand DW; Lum L; Brautigam CA; Pascal JM; Clements WK; Potts PR
Cell Rep; 2020 Jul; 32(3):107922. PubMed ID: 32698014
[TBL] [Abstract][Full Text] [Related]
39. Tankyrase: a promising therapeutic target with pleiotropic action.
Sagathia V; Patel C; Beladiya J; Patel S; Sheth D; Shah G
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3363-3374. PubMed ID: 37338576
[TBL] [Abstract][Full Text] [Related]
40. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]